Surgical considerations in post-programmed cell death-1 therapy for cutaneous squamous cell carcinoma.

Authors

Seo Won Cho, Mojahed Mohammad K Shalabi, Marcus Zaayman, Chad D Housewright

Published in

Proceedings (Baylor University. Medical Center). Pages 1-3. Sep 16, 2026. Epub Sep 16, 2026.

Abstract

Cutaneous squamous cell carcinoma (cSCC) can present as advanced disease requiring systemic therapy. Programmed cell death-1 (PD-1) inhibitors such as cemiplimab enable significant tumor regression. We report a patient with advanced cSCC who achieved near-complete remission after cemiplimab, followed by Mohs surgery revealing unexpected frontal sinus communication. This case underscores the importance of considering underlying structural changes when operating in previously treated areas.

PMID:
42747021
Bibliographic data and abstract were imported from PubMed on 16 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.